AMGN News 121.11 07/23/2014 04:32:54 Amgen Inc (AMGN)
Post# of 273333
Posted On: 07/23/2014 5:32:40 AM
Amgen Inc (AMGN) 121.11 $AMGN
Final Glance: Biotechnology companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...
Midday Glance: Biotechnology companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
PR Newswire - Mon Jul 21, 9:00AM CDT
Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages this proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has over other statin add-on therapies are due to its highly efficacious LDL-C lowering capabilities and the potential to reduce the risk of cardiovascular disease.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Colorado BioScience Association Recognizes Amgen Foundation's $25,000 Investment in STEM Education in Colorado's Classrooms
Business Wire - Mon Jul 21, 8:00AM CDT
The Colorado BioScience Association (CBSA) is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute (CBSI) in support of the Research Experience for Teachers (RET) program, in addition to funds provided by others including The Anschutz Foundation. The announcement is made by CBSA/CBSI President & CEO April Giles, who says, "We are honored to receive these grants for our RET program and know it will make a positive impact in Colorado's science classrooms."
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
Amgen (AMGN) Breaks Through Resistance at $116.64
Comtex SmarTrend(R) - Fri Jul 18, 9:01AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $115.92 today and has reached the first level of resistance at $116.64. Investors may be interested in a cross of the next upside pivot targets of $117.88 and $119.84.
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Thu Jul 17, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.
Final Glance: Biotechnology companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...
Midday Glance: Biotechnology companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
PR Newswire - Mon Jul 21, 9:00AM CDT
Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages this proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has over other statin add-on therapies are due to its highly efficacious LDL-C lowering capabilities and the potential to reduce the risk of cardiovascular disease.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Colorado BioScience Association Recognizes Amgen Foundation's $25,000 Investment in STEM Education in Colorado's Classrooms
Business Wire - Mon Jul 21, 8:00AM CDT
The Colorado BioScience Association (CBSA) is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute (CBSI) in support of the Research Experience for Teachers (RET) program, in addition to funds provided by others including The Anschutz Foundation. The announcement is made by CBSA/CBSI President & CEO April Giles, who says, "We are honored to receive these grants for our RET program and know it will make a positive impact in Colorado's science classrooms."
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
Amgen (AMGN) Breaks Through Resistance at $116.64
Comtex SmarTrend(R) - Fri Jul 18, 9:01AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $115.92 today and has reached the first level of resistance at $116.64. Investors may be interested in a cross of the next upside pivot targets of $117.88 and $119.84.
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Thu Jul 17, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.
(0)
(0)